ClinicalTrials.gg
Active, not recruitingNCT06398626ENDEAVOUR-UCUpdated Nov 17, 2026

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

An observational study in Colitis, Ulcerative, sponsored by Pfizer. Active, not recruiting at 26 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pfizer · Observational

How we know

Updated Nov 17, 2026Now Active, not recruitingStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Colitis, Ulcerative by Pfizer — 2 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.

Enrollment
8th of 16
300 · median 276
Started
2024
with 1 other
Observational
16 of 42
none open now
Registered
39th of 42
by date

Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 8th largest by enrollment of the 16 observational ones that give a count, is one of 2 that started in 2024, is one of 16 observational ones, and was the 39th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colitis, Ulcerative by Pfizer, or all of them as a file.
02

Study summary

The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod.

All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer.

The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the United States etrasimod prescribing information and independent from the decision to enroll the patient in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and \< 65 years at baseline
  2. Patients with confirmed diagnosis of UC who are prescribed etrasimod for moderately to severely active UC
  3. Evidence of a personally signed and dated ICD indicating that the patient (or a legally acceptable representative)has been informed of all pertinent aspects of the study

Exclusion criteria

Exclusion Criteria:

  1. The presence of clinical findings suggestive of Crohn's disease
  2. Severe extensive colitis evidenced by:

    1. Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (e.g., colectomy) within 12 weeks
    2. Current evidence of acute severe UC, fulminant colitis, or toxic megacolon
  3. Patients with a stoma or planned UC surgical intervention requiring hospitalization
  4. Prior/Concomitant Therapy:

    1. Any previous exposure to etrasimod, including participation in the etrasimod clinical program
    2. Any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine, or tioguanine)
    3. Any co-medication with one of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist; JAKi [filgotinib, tofacitinib, or upadacitinib]) or with any other S1P receptor modulator
  5. Unwillingness or inability to download the web-based tool to complete ePROs on a personal device or not capable of using the web-based tool
  6. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • Adult patients with ulcerative colitis taking etrasimod

    Drug: Etrasimod

Interventions

  • As provided in real world practice

06

What researchers measure

Primary outcomes

  1. Proportion of patients with symptomatic remission

    Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0

    Time frame: Week 12

Secondary outcomes

  1. Proportion of patients with symptomatic remission

    Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0

    Time frame: Weeks 24, 36, 52

  2. Proportion of patients with symptomatic response

    Symptomatic response defined as a decrease from baseline ≥ 30% in pMMS composite RBS and SFS

    Time frame: Weeks 12, 24, 36, 52

  3. Proportion of patients with symptomatic response

    Symptomatic response defined as a decrease from baseline ≥ 20% in pMMS composite RBS and SFS

    Time frame: Weeks 12, 24, 36, 52

  4. Proportion of patients with clinical remission

    Clinical remission is defined as a pMMS ≤ 2 points, with no individual subscores \> 1 point.

    Time frame: Weeks 12, 24, 36, 52

  5. Proportion of patients with steroid-free symptomatic remission (among all patients and among patients in symptomatic remission)

    Steroid-free symptomatic remission is defined as patients in symptomatic remission who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint

    Time frame: Weeks 24, 36, 52

  6. Proportion of patients with steroid-free clinical remission (among all patients and among patients in clinical remission)

    Steroid-free clinical remission is defined as patients in clinical remission (using a pMMS) who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint

    Time frame: Weeks 24, 36, 52

  7. Change from baseline in fatigue

    Change from baseline in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score Normalization of fatigue is defined as a FACIT Fatigue score ≥ 40.1

    Time frame: Weeks 12, 24, 36, 52

  8. Change from baseline of bowel urgency

    Change from baseline in bowel urgency on a 0 (no urgency) - 10 (worst possible urgency) numeric rating scale

    Time frame: Weeks 12, 24, 36, 52

  9. Proportion of patients with a clinically meaningful improvement in bowel urgency

    Clinically meaningful improvement in bowel urgency is defined as ≥ 3-point decrease from baseline among patients with baseline bowel urgency score ≥ 3

    Time frame: Weeks 12, 24, 36, 52

  10. Proportion of patients in bowel urgency remission

    Bowel urgency remission is defined as a bowel urgency score ≤ 1 among patients with a baseline bowel urgency score ≥ 3 and the overall population

    Time frame: Weeks 12, 24, 36, 52

  11. Proportion of patients with complete bowel urgency remission

    Complete bowel urgency remission is defined as a bowel urgency Numeric Rating Scale score = 0

    Time frame: Weeks 12, 24, 36, 52

  12. Change from baseline in abdominal pain

    Change from baseline in abdominal pain on a 0 (no pain) - 10 (pain as bad as can imagine) numeric rating scale

    Time frame: Weeks 12, 24, 36, 52

  13. Proportion of patients with abdominal pain remission

    Abdominal pain remission is defined as an abdominal pain Numeric Rating Scale score = 0

    Time frame: Weeks 12, 24, 36, 52

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 36 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 3, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Sites
1 site added, 3 sites removed
Show site
  • Gastro Florida · Lutz, United States
Show 3 removed
  • United Medical Doctors · Los Alamitos, United States
  • Gastro Florida · Lutz, United States
  • Brooke Army Medical center · San Antonio, United States
across 2 updates, Oct 26, 2026 – Nov 17, 2026
Study completion
Jul 7, 2028→Jul 1, 2028
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    3 sites removed
    Show 3 removed
    • United Medical Doctors · Los Alamitos, United States
    • Gastro Florida · Lutz, United States
    • Brooke Army Medical center · San Antonio, United States
    Study completion Jul 7, 2028→Jul 1, 2028
    + 3 other changes: identifiers, verification date and contact details
  2. Oct 26, 2026
    1 site added. 2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • United Medical Doctors · Los Alamitos, United StatesRecruiting→Not yet recruiting
    • United Medical Doctors · Los Alamitos, United StatesNot yet recruiting→Recruiting
    Show site
    • Gastro Florida · Lutz, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06398626
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Sep 17, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion